SELLAS Life Sciences Group (NASDAQ:SLS) Reaches New 1-Year High – What’s Next?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) reached a new 52-week high on Wednesday . The company traded as high as $8.28 and last traded at $8.9910, with a volume of 376791 shares. The stock had previously closed at $7.59.

Analyst Upgrades and Downgrades

Several research firms recently commented on SLS. Maxim Group increased their price objective on SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Thursday, March 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $10.00.

SELLAS Life Sciences Group Price Performance

The firm has a fifty day moving average of $5.14 and a 200 day moving average of $3.82. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of -38.02 and a beta of 2.24.

SELLAS Life Sciences Group (NASDAQ:SLS) last issued its earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01.

Hedge Funds Weigh In On SELLAS Life Sciences Group

A number of institutional investors have recently bought and sold shares of SLS. Axxcess Wealth Management LLC purchased a new stake in shares of SELLAS Life Sciences Group in the 3rd quarter valued at approximately $26,000. Larson Financial Group LLC acquired a new stake in shares of SELLAS Life Sciences Group during the 4th quarter worth about $26,000. BNP Paribas Financial Markets raised its holdings in SELLAS Life Sciences Group by 89.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock valued at $32,000 after buying an additional 9,299 shares during the period. Concurrent Investment Advisors LLC acquired a new stake in shares of SELLAS Life Sciences Group during the fourth quarter valued at about $38,000. Finally, Beacon Pointe Advisors LLC purchased a new position in shares of SELLAS Life Sciences Group during the 4th quarter worth approximately $38,000. 17.38% of the stock is owned by hedge funds and other institutional investors.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.